Facing the Challenges in Vaccine Upstream Bioprocessing - 9

TUTORIAL

Scalable Production
of AAV Vectors
Range of Methods Used in Generating
and Purifying AAV Vectors

T

he Vectors derived from adeno-associated
virus (AAV) provide promising gene delivery vehicles that can be used effectively in
large-scale productions for preclinical target
identification/validation studies, or used in
large animal models and clinical trials of human
gene therapy.

9

| GENengnews.com

Why is AAV one of the most promising viral
gene transfer vectors? Notably, recombinant
adeno-associated virus (rAAV) vectors come
in different serotypes (AAV 1-9), each with
different tissue tropisms. rAAV provides a high
rate of gene transfer efficiency, long-term gene
expression, and natural replication deficiency.
It is nonpathogenic and does not have the
capability of altering biological properties upon
integration of the host cell.

ADDITIONAL CONTENT
Scale-down models are important to optimize
a bioprocess, troubleshoot, and implement
changes. Researchers at Généthon describe
scale-down model development for a viral
vector production process in Sf9 cells.
Read application note

4X-image/Getty Images

Eva Szarek, Ph.D., and
Jeffrey Hung, Ph.D.



http://www.eppendorf.com/appnote303 http://www.GENengnews.com

Facing the Challenges in Vaccine Upstream Bioprocessing

Table of Contents for the Digital Edition of Facing the Challenges in Vaccine Upstream Bioprocessing

Contents
Facing the Challenges in Vaccine Upstream Bioprocessing - 1
Facing the Challenges in Vaccine Upstream Bioprocessing - 2
Facing the Challenges in Vaccine Upstream Bioprocessing - 3
Facing the Challenges in Vaccine Upstream Bioprocessing - Contents
Facing the Challenges in Vaccine Upstream Bioprocessing - 5
Facing the Challenges in Vaccine Upstream Bioprocessing - 6
Facing the Challenges in Vaccine Upstream Bioprocessing - 7
Facing the Challenges in Vaccine Upstream Bioprocessing - 8
Facing the Challenges in Vaccine Upstream Bioprocessing - 9
Facing the Challenges in Vaccine Upstream Bioprocessing - 10
Facing the Challenges in Vaccine Upstream Bioprocessing - 11
Facing the Challenges in Vaccine Upstream Bioprocessing - 12
Facing the Challenges in Vaccine Upstream Bioprocessing - 13
Facing the Challenges in Vaccine Upstream Bioprocessing - 14
Facing the Challenges in Vaccine Upstream Bioprocessing - 15
Facing the Challenges in Vaccine Upstream Bioprocessing - 16
Facing the Challenges in Vaccine Upstream Bioprocessing - 17
Facing the Challenges in Vaccine Upstream Bioprocessing - 18
Facing the Challenges in Vaccine Upstream Bioprocessing - 19
Facing the Challenges in Vaccine Upstream Bioprocessing - 20
Facing the Challenges in Vaccine Upstream Bioprocessing - 21
Facing the Challenges in Vaccine Upstream Bioprocessing - 22
Facing the Challenges in Vaccine Upstream Bioprocessing - 23
Facing the Challenges in Vaccine Upstream Bioprocessing - 24
Facing the Challenges in Vaccine Upstream Bioprocessing - 25
Facing the Challenges in Vaccine Upstream Bioprocessing - 26
Facing the Challenges in Vaccine Upstream Bioprocessing - 27
Facing the Challenges in Vaccine Upstream Bioprocessing - 28
Facing the Challenges in Vaccine Upstream Bioprocessing - 29
Facing the Challenges in Vaccine Upstream Bioprocessing - 30
Facing the Challenges in Vaccine Upstream Bioprocessing - 31
Facing the Challenges in Vaccine Upstream Bioprocessing - 32
Facing the Challenges in Vaccine Upstream Bioprocessing - 33
Facing the Challenges in Vaccine Upstream Bioprocessing - 34
Facing the Challenges in Vaccine Upstream Bioprocessing - 35
https://www.nxtbookmedia.com